Treatment of inflamed pterygia or residual pterygial bed
- 1Department of Ophthalmology, American University of Beirut, Beirut, Lebanon
- 2Rafic Hariri University Hospital, Beirut, Lebanon
- Professor A M Mansour, Department of Ophthalmology, American University of Beirut, PO Box 113-6044, Beirut, Lebanon; dr.ahmad{at}cyberia.net.lb
- Accepted 22 February 2009
Abstract
Aims: To describe the use of subconjunctival bevacizumab or ranibizumab, an approved antivascular endothelial growth factor for wet macular degeneration, in halting the inflammation of a pterygium or a partially excised pterygium.
Methods: Case reports.
Results: Prompt regression of conjunctival microvessels in the pterygial bed was documented 1 week after a single subconjunctival injection of ranibizumab (one case) or bevacizumab (two cases). No side-effects were noted over 13 months of follow-up in the first case, 6 months in the second case and 1 month in the third case.
Conclusion: Selective blockade of vascular endothelial growth factor was effective in causing regression of conjunctival microvessels in three eyes with inflamed pterygium or residual pterygia.
Footnotes
-
Competing interests: None.
-
Ethics approval: Ethics approval was provided by Rafic Hariri University Hospital, Affiliate American University of Beirut.
-
Patient consent: Obtained.
